(1) Backed by robust demand by the Pharma industry, (2) 15kTPA capacity addition of Methyl Amines at Dahej, and (3) Enhanced Acetonitrile capacity by 15kTPA to 33, will help AACL garner market share. With strong return ratios (RoIC of >25% over FY20-22E) and attractive valuations (trading at 13.3/11.6 FY21/22E EPS), Alkyl Amines is our top pick in the Chemicals space. We maintain BUY on AACL post a beat on our EBITDA estimates in 1HFY20. We bump-up our EBITDA margins by ~200-300bps over FY20-22 to factor in AACLs enhanced bargaining power and improved product mix. Our revised target price is Rs 1,770 (22x Sep-FY21 EPS).